Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Adiyaman University, 02040 Adiyaman, Turkey.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Adiyaman University, 02040 Adiyaman, Turkey.
Bioorg Med Chem. 2019 Apr 15;27(8):1588-1594. doi: 10.1016/j.bmc.2019.03.001. Epub 2019 Mar 1.
A series of twenty novel ureido benzenesulfonamides incorporating 1,3,5-triazine moieties substituted on one side with aromatic amines and on the other side with dimethylamine, morpholine and piperidine is reported. The compounds were synthesized from the 4-(3-(4,6-dichloro-1,3,5-triazin-2-yl)ureido)benzensulfonamide (1) by using stepwise nucleophilic substitution of the chlorine atoms of cyanuric chloride. The intermediates 2(a-e) and final compounds 3(a-o) were tested for their efficiency as carbonic anhydrase (CA) inhibitors against four selected physiologically relevant human carbonic anhydrase (CA, EC 4.2.1.1) isoforms, namely, the cytosolic ones hCA I and II, and the transmembrane, tumor associated ones hCA IX, and XII. The compounds 2a, 2e and 3m showed the highest activity for hCA IX with Ks in the range of 11.8-14.6 nM. Most of the compounds showed high hCA IX selectivity over the abundant off-target isoforms hCA I and II. Since hCA IX is a validated drug target for anticancer/antimetastatic agents, these isoform-selective and potent inhibitors may be considered of interest for further medicinal/pharmacologic studies.
报道了一系列二十种新型的脲基苯磺酰胺化合物,这些化合物在一侧带有芳香胺,另一侧带有二甲胺、吗啉和哌啶取代的 1,3,5-三嗪部分。这些化合物是由 4-(3-(4,6-二氯-1,3,5-三嗪-2-基)脲基)苯磺酰胺(1)通过氰尿酸氯的逐步亲核取代合成的。中间体 2(a-e)和最终化合物 3(a-o)被测试了它们作为碳酸酐酶(CA)抑制剂的效率,针对四种选定的生理相关的人碳酸酐酶(CA,EC 4.2.1.1)同工酶,即细胞溶质同工酶 hCA I 和 II,以及跨膜、肿瘤相关同工酶 hCA IX 和 XII。化合物 2a、2e 和 3m 对 hCA IX 的活性最高,Ks 值在 11.8-14.6 nM 范围内。大多数化合物对丰富的非靶标同工酶 hCA I 和 II 具有高的 hCA IX 选择性。由于 hCA IX 是抗癌/抗转移药物的有效靶标,因此这些同工酶选择性和有效的抑制剂可能被认为具有进一步的医学/药理学研究的意义。